UK markets closed

BioNTech SE (22UA.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
91.79-1.15 (-1.24%)
At close: 7:47PM CET
Full screen
Previous close92.94
Open90.60
Bid0.00 x N/A
Ask0.00 x N/A
Day's range90.50 - 94.10
52-week range25.44 - 109.48
Volume11,688
Avg. volume52,639
Market cap21.948B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.78
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • J&J single-dose COVID-19 vaccine recommended for emergency use
    Editor's pick
    Yahoo Finance

    J&J single-dose COVID-19 vaccine recommended for emergency use

    J&J's vaccine recommended for emergency use authorization by independent experts. FDA will make a decision this weekend.Johnson & Johnson's (JNJ) single-dose COVID-19 vaccine is one step closer to emergency use authorization (EAU) after an independent panel voted Friday to recommend the U.S. Food and Drug Administration (FDA) issue the EUA.

  • Pfizer-BioNTech testing booster of their COVID-19 vaccine in new trial
    Reuters

    Pfizer-BioNTech testing booster of their COVID-19 vaccine in new trial

    Pfizer Inc and BioNTech SE said on Thursday they are testing a third dose of their COVID-19 vaccine to better understand the immune response against new variants of the virus. They are also in talks with regulatory authorities about testing a vaccine modified to protect specifically against the highly transmissible new variant found in South Africa and elsewhere, known as B.1.351, as a second arm of the same study. The companies believe their current two-dose vaccine will work against the South African variant as well as one found in the United Kingdom and elsewhere.

  • Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
    Business Wire

    Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants

    Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the effect of a booster on immunity against COVID-19 caused by the circulating and potential newly emerging SARS-CoV-2 variants. The study will draw upon participants from the Phase 1 study in the United States who will be offered the opportunity to receive a 30 µg booster of the current vaccine 6 to 12 months after receiving their initial two-dose regimen. The study is part of the Companies’ clinical development strategy to determine the effectiveness of a third dose against evolving variants.